Origin of marine planktonic cyanobacteria by Sanchez-Baracaldo, Patricia
                          Sanchez-Baracaldo, P. (2015). Origin of marine planktonic cyanobacteria.
Scientific Reports, 5, [17418]. DOI: 10.1038/srep17418
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1038/srep17418
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Nature at
http://www.nature.com/articles/srep17418. Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms.html
Protocol
Normothermic Versus Hypothermic Cardiopulmonary Bypass in
Children Undergoing Open Heart Surgery (Thermic-2): Study
Protocol for a Randomized Controlled Trial
Sarah Baos1, PhD; Karen Sheehan2, RGN, RSCN, MSc; Lucy Culliford1, PhD; Katie Pike1, MSc; Lucy Ellis1, MRes;
Andrew J Parry2,3, DM (Oxon),FRCS (CTh) (Eng); Serban Stoica2, FRCS (CTh), MD; Mohamed T Ghorbel3, PhD;
Massimo Caputo2, MD; Chris A Rogers1, PhD
1Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom
2Bristol Royal Hospital for Children, Division of Women and Children, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
3Bristol Heart Institute, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
Corresponding Author:
Chris A Rogers, PhD
Clinical Trials and Evaluation Unit
School of Clinical Sciences
University of Bristol
Level 7 Queen's Building
Bristol Royal Infirmary
Bristol, BS2 8HW
United Kingdom
Phone: 44 0 117 342 2507
Fax: 44 0 117 342 3288
Email: chris.rogers@bristol.ac.uk
Abstract
Background: During open heart surgery, patients are connected to a heart-lung bypass machine that pumps blood around the
body (“perfusion”) while the heart is stopped. Typically the blood is cooled during this procedure (“hypothermia”) and warmed
to normal body temperature once the operation has been completed. The main rationale for “whole body cooling” is to protect
organs such as the brain, kidneys, lungs, and heart from injury during bypass by reducing the body’s metabolic rate and decreasing
oxygen consumption. However, hypothermic perfusion also has disadvantages that can contribute toward an extended postoperative
hospital stay. Research in adults and small randomized controlled trials in children suggest some benefits to keeping the blood
at normal body temperature throughout surgery (“normothermia”). However, the two techniques have not been extensively
compared in children.
Objective: The Thermic-2 study will test the hypothesis that the whole body inflammatory response to the nonphysiological
bypass and its detrimental effects on different organ functions may be attenuated by maintaining the body at 35°C-37°C
(normothermic) rather than 28°C (hypothermic) during pediatric complex open heart surgery.
Methods: This is a single-center, randomized controlled trial comparing the effectiveness and acceptability of normothermic
versus hypothermic bypass in 141 children with congenital heart disease undergoing open heart surgery. Children having scheduled
surgery to repair a heart defect not requiring deep hypothermic circulatory arrest represent the target study population. The
co-primary clinical outcomes are duration of inotropic support, intubation time, and postoperative hospital stay. Secondary
outcomes are in-hospital mortality and morbidity, blood loss and transfusion requirements, pre- and post-operative echocardiographic
findings, routine blood gas and blood test results, renal function, cerebral function, regional oxygen saturation of blood in the
cerebral cortex, assessment of genomic expression changes in cardiac tissue biopsies, and neuropsychological development.
Results: A total of 141 patients have been successfully randomized over 2 years and 10 months and are now being followed-up
for 1 year. Results will be published in 2015.
Conclusions: We believe this to be the first large pragmatic study comparing clinical outcomes during normothermic versus
hypothermic bypass in complex open heart surgery in children. It is expected that this work will provide important information
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to improve strategies of cardiopulmonary bypass perfusion and therefore decrease the inevitable organ damage that occurs during
nonphysiological body perfusion.
Trial Registration: ISRCTN Registry: ISRCTN93129502, http://www.isrctn.com/ISRCTN93129502 (Archived by WebCitation
at http://www.webcitation.org/6Yf5VSyyG).
(JMIR Res Protoc 2015;4(2):e59)   doi:10.2196/resprot.4338
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Introduction
Background
The treatment of many forms of congenital heart disease has
continued to advance, and primary early repairs of an increasing
number of defects are routinely performed (eg, atrioventricular
canal, tetralogy of Fallot, transposition of the great arteries). At
Bristol Royal Hospital for Children (BRHC) an average of 285
cardiac operations are performed a year, and approximately
75% (ie, an average of 210) require cardiopulmonary bypass
(CPB). Despite its widespread use, there is still significant
morbidity related to the nonphysiological nature of total CPB
[1]. Whole body cooling (ie, hypothermia) is an integral part
of congenital cardiac surgery, with most procedures being
conducted between 28°C and 30°C, depending on the expected
duration and type of operation. The main rationale for body
cooling is to protect organs such as the brain, kidneys, and heart
from ischemic injury by reducing the metabolic rate and, hence,
oxygen consumption [1]. Nevertheless, hypothermia has a
number of disadvantages, including detrimental effects on
enzymatic function, energy generation, and cellular integrity
[1]. Perfusion of the body and the brain at normal body
temperature (ie, normothermia) is a potentially more
physiological method to maintain the functional integrity of
major organ systems, and in recent years there has been an
increasing interest in normothermic CPB in adult and pediatric
cardiac surgery [2-9]. The concept that normothermic systemic
perfusion may confer certain advantages over hypothermic
regimes arose fortuitously from adult clinical experience in
which an absence of shivering, hemodynamic stability, minimum
use of inotropes, and early extubation were observed when
patients were not cooled [2]. This led several investigators to
study the effects of systemic hypothermia and normothermic
perfusion upon cellular and organ function [2,10-14].
In both adult and pediatric cardiac surgery, many of the
detrimental effects of CPB on end organ dysfunction were
previously believed to be mediated by activation of the
inflammatory response [1,15]. One may expect that CPB-related
systemic inflammatory response syndrome and multiorgan
injury to be enhanced during normothermia, since most
enzymatic processes occur optimally at 37°C. Supportive of
this notion are clinical studies in adults [16] in which
normothermic CPB (35°C-37°C) was associated with
significantly elevated levels of inflammatory markers compared
to hypothermic CPB (28°C-30°C). Consistent with this, previous
animal data have shown that the inflammatory response is
reduced by hypothermia [17,18]. However, a conflicting picture
is emerging from research. Ohata et al [19] have demonstrated
an attenuation of certain inflammatory mediators following
warm systemic perfusion (34°C) compared to hypothermic
perfusion (28°C). In a clinical study at the Bristol Heart Institute
[10,20], normothermic (37°C) perfusion was also associated
with attenuation of inflammatory mediator release in the
postoperative period, compared to moderately hypothermic
(32°C) and hypothermic CPB (28°C). In contrast, others have
suggested that induction of a systemic response is not
temperature dependent. Rasmussen et al have shown that the
release of systemic inflammatory mediators after cardiac surgery
in adults was independent of mild hypothermia (32°C) when
compared to normothermia (36°C) [21]. A randomized
controlled trial (RCT) in 66 children having open heart surgery,
who were randomized to either moderate hypothermia (24°C)
or mild hypothermia (34°C), found that neither the systemic
inflammatory response nor organ injury were influenced by
bypass temperature [22]. Eggum et al demonstrated that there
were only minor differences in inflammatory marker
concentrations between pediatric patients undergoing moderate
(25°C) hypothermia and those with mild (32°C) hypothermia
during CPB [23]. This evidence was supported by an RCT
carried out at BRHC comparing warm (35°C-37°C) and cold
(28°C) CPB on simple congenital cardiac malformations, which
indicated that both whole body inflammatory response and
myocardial reperfusion injury were similar between the 2 groups
[24]. In addition, Caputo et al and Eggum et al demonstrated
that normothermic CPB was associated with reduced oxidative
stress compared with hypothermic CPB. Other researchers have
studied the effect of the temperature of the cardioplegia during
pediatric cardiac surgery [25,26]. Poncelet et al have taken this
a step further by studying the effect of the temperature of the
CPB in addition to the cardioplegia in an RCT on 47 children
having cardiac surgery [27]. In this study, children were
randomized to either mild hypothermia with cold crystalloid
cardioplegia (CPB temperature 32°C, cardioplegia at 5°C) or
normothermic with intermittent warm blood cardioplegia (CPB
temperature 36.5°C). They found no significant difference in
the cellular ischemic insult to the heart or in the early and late
neurodevelopmental status of the patients. With conflicting
evidence arising from clinical trials comprising relatively low
numbers of patients and mainly simple cardiac surgery cases,
it is difficult to establish whether the induction of a systemic
response is temperature dependent and the impact this may have
on clinical outcome. This warrants a larger study with clinical
outcomes as primary endpoints.
Aim
The Thermic-2 study (Current Controlled Trials
ISRCTN93129502) will compare the clinical effectiveness of
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normothermic (35°C-37°C) versus hypothermic (28°C) CPB
for the repair of common congenital cardiac pathologies. We
will test the hypothesis that maintaining the body at 35°C-37°C
(normothermia) rather than at 28°C (hypothermia) during
pediatric open heart surgery reduces the whole body
inflammatory response to the nonphysiological CPB and its
detrimental effects on different organ functions, resulting in a
better clinical outcome.
Methods
Study Design
This study is a single-center, parallel-group open RCT. The
study schema is shown in Figure 1.
Figure 1. Study schema showing the participant recruitment pathway.
Research Approval
Research ethics approval was granted by the National Research
Ethics Service Committee South West—Central Bristol
(reference 11/SW/0122) in October 2011. The study is registered
(ISRCTN 93129502).
Study Population
All pediatric patients (aged 18 years and younger) having
scheduled surgery at the BRHC to repair a congenital heart
defect using CPB, represent the target study population and will
be screened for eligibility. Patients will be excluded from the
study if either: (1) they require deep hypothermic circulatory
arrest, (2) they are admitted for an emergency operation (patients
with hemodynamic instability who require immediate surgical
intervention), or (3) they and/or their next-of-kin do not provide
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written informed consent. We will also record specific reasons
where surgeons are unwilling for the patient to be approached
for the study. All reasons for ineligibility will be recorded on
the study screening log.
We will aim to approach all next-of-kin (usually parents) and/or
patients at preoperative clinics or on admission the day before
surgery. Eligible next-of-kin and/or patients will be given a
patient information leaflet (PIL), have the study explained to
them, and will be given the opportunity to ask questions about
the study. They will be given a minimum of 24 hours to consider
the study prior to being asked to provide written informed
consent if they are willing to participate in the study.
Randomization
Participants will be randomly assigned in a 1:1 ratio to either
the hypothermic group or the normothermic group.
Randomization will be stratified by age: 1 month or younger,
1 to 12 months, and older than 12 months. Allocations will be
generated by computer using block randomization with varying
block sizes. The allocation sequence will be prepared in advance
of the study by a statistician independent of the study team. If
a participant’s surgery is unexpectedly rescheduled, he/she will
retain his/her study numbers and randomized allocation. Access
to the allocation will be via a password-controlled secure
database. Randomization will take place as close to the start of
surgery as possible.
Study Interventions
Participants will be randomized to receive either hypothermic
or normothermic CPB during their surgery into the following
groups:
1. Hypothermic CPB: cardiopulmonary bypass with perfusion
at 28°C (control)
2. Normothermic CPB: cardiopulmonary bypass with
perfusion at 35°C-37°C (experimental)
Cardiopulmonary Bypass
All operations will be performed using CPB with ascending
aortic cannulation and bicaval venous cannulation (Figure 2).
Cold St Thomas’ I-based blood cardioplegic solution (4°C-6°C)
will be used for myocardial preservation in all participants
(Martindale Pharmaceuticals Ltd) with the following
composition: 16 mM MgCl2, 2 mM CaCl2, 20 mM KCl, 147
mM NaCl, and 1 mM procaine HCl. Cardioplegic arrest will
be achieved by an antegrade infusion of 110 ml/m2/min for 4
minutes. Additional cardioplegia will be administered after 20
minutes of aortic cross-clamping. Intramyocardial temperature
will be monitored by means of a temperature probe inserted
every 10 minutes into the right and left ventricles during
ischemic arrest. For all participants, concomitant rectal,
nasopharyngeal, skin, and blood temperatures will be monitored
throughout the operation.
Figure 2. Image showing the heart of a child born with an atrial septal defect (ASD). The heart has been emptied of blood, put on cardiopulmonary
bypass (CPB), and arrested using the cardioplegia solution, which is injected into the aortic root after the aorta is cross-clamped. CPB is achieved by
inserting a superior vena cava (SVC) and an inferior vena cava (IVC) cannula for the venous drainage and an aortic cannula for the arterial perfusion
of the body. The right atrium is open and the ASD is clearly visible.
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Hypothermic CPB
Nasopharyngeal body temperature will be lowered to 28°C.
Rewarming will commence at the completion of the anatomical
correction. All participants will be rewarmed with a temperature
difference of 8°C at the level of the heat exchanger between the
blood and the rewarming fluid, and CPB will be discontinued
only after the participant is fully rewarmed to 36°C.
Normothermic CPB
Nasopharyngeal body temperature will be maintained at
35°C-37°C. Rewarming will only take place in the
normothermic group if the body temperature is <36°C and will
be discontinued only after the participant is fully rewarmed to
37°C.
Anesthesia
Induction of anesthesia will be gaseous induction with
sevoflurane, administration of neuromuscular blockade using
pancuronium and analgesia using bolus dose fentanyl (10
mcg/kg-20 mcg/kg) pre-CPB, and morphine (0.5 mg/kg) during
CPB. Maintenance of anesthesia will be with isoflurane. Alpha
stat acid-base management will be adopted. Initial
anticoagulation will be accomplished with 3 mg/kg to 4 mg/kg
body weight of heparin and supplemented as required in order
to maintain an active clotting time of ≥480 seconds.
Deviations from this standardized anesthetic technique are
permissible under the following conditions:
1. Intravenous induction using ketamine, propofol, or
thiopentone may be used if the anesthetist considers
sevoflurane to be unsuitable for induction for the patient.
2. Where pancuronium is not available, vecuronium or
rocuronium may be used instead.
3. Propofol instead of isoflurane may be used for maintenance
of anesthesia where the anesthetist considers the patient to
be at increased risk of awareness.
Study Center and Surgeons
Overview
All surgery will be carried out at BRHC. On average, 210
pediatric cardiac surgery procedures using CPB are performed
per year at this center. All the pediatric cardiac surgeons at this
center are participating in the study.
Primary Outcomes
The co-primary endpoints are (1) duration of inotropic support,
(2) intubation time, and (3) postoperative hospital stay (from
date of surgery to discharge from cardiac ward). These data will
be collected from medical notes and hospital charts.
Secondary outcomes
Data will be collected to characterize the following secondary
outcomes:
1. In-hospital mortality and morbidity rates will be recorded.
2. Blood loss and transfusion requirements will be recorded.
3. Preoperative and postoperative echocardiographic (ECG)
findings will be recorded.
4. Routine blood gas and blood test results will be recorded.
5. Renal function will be measured by testing urinary albumin,
urinary creatinine, retinal binding protein (RBP),
N-acetyl-β-glucosaminidase (NAG), and neutrophil
gelatinase-associated lipocalin (NGAL) [28-33]. All
markers of renal damage will be measured preoperatively
and at several time-points postoperatively.
6. Cerebral function will be measured by testing for glial
fibrillary acidic protein (GFAP), a serum marker of
traumatic brain injury [34,35]. GFAP levels will be
measured preoperatively and at several time-points mid-
and postoperatively.
7. Regional oxygen saturation of blood in the cerebral cortex
will be measured at approximately 15-minute intervals
during the operative period using near-infrared spectroscopy
(NIRS).
8. Neuropsychological development will be assessed using
the NEPSY-II psychometric tool [36]. Neuropsychological
assessments will be performed on patients aged between
3-16 years old, preoperatively and at 3 and 12 months
postoperatively. These tests are intended as a tool to allow
the assessment of both basic and complex aspects of
cognition across the following 6 functional domains:
attention and executive functions, language, memory and
learning, sensorimotor functions, social perception, and
visual-spatial processing.
9. Cardiac tissue biopsies from heart tissue discarded during
the surgical procedure and considered clinical waste will
be analyzed for biochemical markers and RNA analysis on
a subset of 32 patients. If available, 4 samples will be
collected from each patient in this subset; 2 samples will
be collected immediately after institution of CPB and a
further 2 samples will be collected 10-15 minutes after
reperfusion. Biochemical tests will be performed on the
biopsies to determine the presence of a range of important
proteins and metabolites, and transcriptional profiling by
RNA extraction will be performed with the aim to help
establish whether any genomic expression changes
associated with hypothermia could be prevented by using
normothermic techniques.
Assessment of Outcomes and Blinding
Participants and their parents/guardians will be blinded to the
treatment allocation. Participants will receive the same surgical
procedure as if they had not joined the study—with the
exception of the temperature of the blood during CPB—and
will receive the same surgical care following the procedure. At
the start of the operation, the perfusion team is given the
treatment allocation in a concealed envelope, asked to follow
the study allocation, and record any reasons for protocol
deviations. Surgeons, anesthetists, and nurses involved in the
operation will be unblinded but the randomization allocation
will not be disclosed until after the start of the operation.
Because surgeons, anesthetists, and nurses continue to care for
participants in the pediatric intensive care unit (PICU) and on
the ward, it is difficult to maintain blinding in these locations.
Where possible, staff will be blinded to the treatment group to
which a participant is assigned. The PICU and ward nursing
teams, while not being actively informed of the patient’s study
allocation, could become unblinded because they have access
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to the anesthetic and perfusion charts that must be stored in the
medical notes. However, it is unlikely that the nursing team
would check the temperature at which the operation was
performed or alter the patient’s after-care since the temperature
during CPB would not have any implications on the
postoperative management of the patient.
The primary endpoints of duration of inotropic support,
intubation time, and postoperative hospital stay should all be
objective outcomes and were chosen primarily as they are
clinically meaningful to the patients and surgeons. While these
outcomes could potentially be influenced by the clinical care
team, the care team must not only adhere to strict protocols and
guidelines, but there is also not a strong expectation that either
arm of the study would be more beneficial to the participant;
therefore, performance and detection bias are minimized.
Outcomes such as in-hospital mortality and morbidity, blood
loss and transfusion requirements, routine blood gas, blood
sample/test results, and regional oxygen saturation of blood in
the cerebral cortex are objective outcomes and will be recorded
directly from medical notes, PICU charts, and electronic records.
Preoperative and postoperative ECG findings involve some
level of subjectivity and judgement; however, ECGs will be
interpreted by a cardiologist blinded to treatment allocation.
Renal function analysis, cerebral function analysis, cardiac
tissue function analysis, and NEPSY-II test administration are
not part of routine care, and assessment will be carried out by
blinded researchers. Reasons for noncompletion of tests or
assays will be recorded.
Data and Sample Collection Schedule
The schedule for data and sample collection is shown in Table
1.
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Table 1. Schedule of data and sample collection.
PostoperativePerioperativePreoperativeData and samples
collected
12
mo
3
moe
Dis-
charge
XC+
72h
XC+
48h
XC+
24h
XC+
6h
XC+
4h
XC+
2hd
XC+
30mc
XCb
re-
moval
10m
post
CPB
Start
of
CPBa
Pre-surgery
✓fEligibility
✓Consent
✓✓✓NEPSY-IIg
✓Baseline data
✓Randomization
✓✓✓✓✓✓Routine blood gases
✓✓✓✓h✓
Routine blood sam-
ples
✓✓✓✓✓✓✓GFAP
✓iNIRS
✓✓✓✓j✓Urine samples
✓✓Cardiac tissue biop-
sies
✓k✓✓✓Operative details
✓Clinical outcomes
✓✓l✓✓✓✓Safety data
aCPB: cardiopulmonary bypass
bXC: cross clamp
cm: minutes
dh: hours
emo: months
f✓ = data/sample collected
gOnly performed on participants eligible for NEPSY-II psychometric assessment.
hRoutine blood samples taken on admission to PICU.
iAs many NIRS results will be recorded as are taken in theater.
jUrine samples taken at cross-clamp removal/end of CPB.
kOperative details are recorded on cross-clamp removal and chest closure.
lHospital admission questionnaire only administered if 3-month NEPSY administered.
Participant Follow-Up
All primary and most secondary outcomes are assessed while
the participant is in hospital following their surgery. For
NEPSY-II eligible patients, NEPSY assessments will take place
at 3 months and 12 months postoperatively (Figure 1 and Table
1). Safety data will also be collected at these visits. For
participants that are not eligible for NEPSY-II assessments,
follow-up for safety will occur at 12 months postoperatively by
postal questionnaire. Active participation for all patients will
cease either at their final NEPSY-II assessment or on return of
the follow-up postal questionnaire, 12 months post operatively.
Sample Size
Primary Outcomes
The geometric mean postoperative hospital stay in our institution
is estimated to be 6.2 days, with standard deviation (on the
logarithmic scale) of 0.4. A sample size of 100 participants per
group would be sufficient to allow us to detect a clinically
relevant 1 day or greater reduction in mean length of stay with
90% power, assuming a 5% level of statistical significance
(2-tailed).
Using estimates for ventilation time and duration of inotropic
support from our institution, a total sample size of 200 would
also be sufficient to detect a 16% reduction in ventilation time
(3 hours), and a 13% reduction in inotropic support (4.7 hours).
All these differences represent clinically relevant reductions.
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In an earlier RCT comparing the same 2 interventions carried
out at our institution (Thermic-1), 59 participants were recruited.
The primary outcomes for this earlier study were biochemical
markers of organ injury, but clinical outcome data were also
collected. For the current study (Thermic-2), 141 participants
have been recruited. The clinical data from the 2 studies will
be combined for assessment of the clinical outcomes, giving a
total sample size of 200 participants for analysis.
Secondary Outcomes
This sample size will also be able to detect clinically relevant
differences in secondary outcomes with 90% power. For full
details, see Multimedia Appendix 1.
Statistical Analyses
Plan of Analysis
Binary outcomes will be compared using logistic regression.
Quantitative outcomes will be transformed if necessary to
achieve approximately normal distributions and compared using
linear regression and time to event variables will be analyzed
using survival methods. Outcomes with repeated measures
(longitudinal data) will be analyzed using mixed models, which
allow for unbalanced data. Alternative correlation structures
will be considered, and the sensitivity of the results to the choice
of structure examined. Analyses will be adjusted for age group
(stratification factor). All analyses will be carried out on the
basis of intention-to-treat. Outcomes will be reported as effect
sizes with 95% confidence intervals.
Specific morbidities are too infrequent for the study to be able
to detect statistically significant differences between groups.
Frequencies of these adverse outcomes will be tabulated, in line
with guidelines for reporting adverse events in trials, and
reported in accordance with International Conference on
Harmonisation Good Clinical Practice guidelines.
The analysis of the microarray data for the gene expression
study—including normalization, noise reduction, and analysis
using, for example, unsupervised hierarchical clustering and
relevance network analysis—will be performed using
Genespring 7 software. Following determination of the gene
expression profiles, bioinformatics data mining tools
(Genespring 7) will be used to identify the gene expression
profiles that are differentially significant and to cluster them by
biological function. This is vital for generating hypotheses about
their role. Predefined stringent criteria will be used to select
candidate genes for validation; only genes with statistically
significant differential expression will be considered. Patterns
of change in signaling pathway networks will be explored.
Subgroup Analyses
Effect estimates for the 2 study phases (Thermic-1 and
Thermic-2) will be examined by adding relevant interaction
terms to the models.
Changes to the Protocol Since First Approved
After recruitment of 52 patients, an amendment was approved
on August 24, 2012, which affected several secondary outcomes:
1. Markers of renal function were incorporated after new
evidence emerged suggesting that normothermic CPB was
associated with similar renal impairment to hypothermic
CPB [31,33].
2. The marker for brain damage was changed from S100-B
to GFAP and samples were taken over 48 hours rather than
24 hours. Evidence has suggested that, when measured
systemically, GFAP is more specific to brain trauma and
may take longer to return to baseline levels than S100-B
levels, which may be elevated during an event such as CPB
or when other organs are damaged or under stress and
independently of whether trauma to the brain has occurred
[37-42].
3. NIRS data collection was incorporated to provide insight
into regional oxygen saturation of the blood in the cerebral
cortex.
In addition, the list of expected adverse events was also updated
to include junctional ectopic tachycardia and heart block. A
second amendment was approved on September 3, 2013, in
which the protocol was updated to clarify the end-of-study
definition, enabling the distinction between the end of study for
an individual participant and for the study as a whole.
Results
A total of 141 patients have been successfully recruited over a
2-year, 10-month period for the Thermic-2 study. The participant
follow-up period will end in October 2015 and results will be
published in late 2015.
Discussion
Principal Findings
While whole body cooling is still very much an integral part of
pediatric cardiac surgery in the belief that it provides some
degree of protection against a systemic inflammatory response
and multiorgan damage, there is little evidence to demonstrate
that this translates to improved clinical outcomes [22-24,31,43].
This may, in part, be due to the multifactorial nature of CPB;
the clinical outcome of a patient is likely to be affected by
factors including the complexity of the anatomical defect being
corrected and the time spent on CPB as well as the temperature
of the CPB. For instance, correction of a simple anatomical
defect performed using hypothermic CPB may attenuate
inflammatory responses and organ damage, however, additional
time spent on CPB to cool and rewarm the patient [22-24] may
offset or mask these effects. In addition, most RCTs
investigating normothermia versus hypothermia do not report
the length of time spent at the allocated temperature, although
through randomization the times should be similar in the 2
groups. Clinically, it is not appropriate to specify how long the
target temperature must be maintained since CPB time should
be kept to a minimum and rewarming must commence on
completion of the anatomical correction. In practice, this results
in shorter, less complex operations that potentially only receive
the intervention for a short time period, while the longer
operations may be exposed to the intervention for a greater
length of time. Furthermore, we do not know how long the target
temperatures of either 28°C or 35°C-37°C need to be maintained
for physiological responses to take effect. While it would be
difficult to impose a specific length of time for treatment
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intervention due to the constraints and complexity of surgery,
it may be useful to collect information regarding the length of
time during which the target temperature was maintained and
this should be considered in future study design.
RCTs in children investigating CPB temperatures have recruited
relatively low numbers of participants and have included the
correction of primarily simple anatomical defects [23,24,27,43].
Furthermore, there is no agreed definition in the current
literature of the reference temperature for hypothermic CPB;
varying from as low as 24°C to up to 32°C, making
interpretation of findings and cross-referencing difficult
[8,22,23,27]. The Thermic-2 study has been designed to collect
data from a large patient population with varying degrees of
congenital heart defect complexity. The outcomes data have
been chosen based on clinical relevance and with the aim to
quantify postoperative course and multiorgan injury, focusing
particularly on the heart, brain, kidney, and lungs. Also, these
clinical parameters have been used to compare the 2 perfusion
techniques in previous studies [8,9,22,27].
Compliance
The study protocol clearly defines the target nasopharyngeal
temperature during CPB to be either 35°C-37°C or 28°C.
However, while the surgeon and theater team may be willing
to follow the allocation, they could be faced with challenges in
order to achieve strict adherence to the study temperature. The
perfusion team responsible for controlling the temperature of
the body throughout CPB are in charge of administering the
allocation. While the perfusion equipment can be used to control
temperature extremely accurately and can be set to hit an exact
target temperature, the circumstances and nature of pediatric
cardiac surgery can result in precise temperature control
becoming a challenge; in practice, it takes time for the body
temperature to change. For clinical reasons, the length of CPB
should be kept to a minimum so the perfusionist must estimate
how fast the body temperature will continue to drift down
toward the target (eg, 28°C) prior to rewarming. This could
result in either over- or under-shooting of the target temperature,
and more often affects the hypothermic group, particularly on
shorter cases, as the rewarming of the body is a clinically
rate-limiting step, and rewarming may have to take place before
the target temperature is reached. Additionally, an open chest,
particularly on very small children, loses heat very quickly, and
consequently the body temperature prior to starting CPB could
drop and there may not be enough time to rewarm the patient
in order reach the target temperature if they were allocated to
the normothermic group (35°C-37°C). Finally, there may be
circumstances when the surgeon may decide that, due to
unforeseen circumstances, it is not clinically appropriate for the
child to participate in the study. In this situation, the surgeon
may dictate what temperature the CPB should be performed at
and the reasons for noncompliance recorded.
Minimization of Bias
The measures outlined below have been put in place to minimize
potential bias: concealed randomization should prevent selection
bias; blinding all possible staff, children, parents/guardians, and
researchers will minimize performance and detection biases;
the majority of outcomes are based on objective criteria; the
PIL; and the process of obtaining informed consent will describe
the uncertainty about the effects of normothermia versus
hyperthermia and, therefore ,there should not be a strong
expectation that one or the other method should lead to a more
favorable result; attrition bias will be minimized by making
every possible effort to keep in touch with participants; the
study will be analyzed on an intention-to-treat basis, and every
effort will be made to include all randomized patients.
Conclusion
In summary, despite the challenges faced in delivering the
temperature allocation during CPB, the study has proceeded
successfully. Lessons learned from Thermic-2 should help to
design and conduct future temperature-based congenital open
heart surgery studies.
Study Status
The study opened to recruitment in November 2011.
Recruitment has recently completed, and follow-up of study
participants continues.
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